Alana L. Welm

Alana L. Welm

Auto-generated profile, based on publicly available information

Alana L. Welm

Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 October 2011 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
YDYoko S DeRose
Yoko S DeRose
GWGuoying Wang
Guoying Wang
YLYi-Chun Lin
Yi-Chun Lin
PBPhilip S Bernard
Philip S Bernard
SBSaundra S Buys
Saundra S Buys
AWAlana L Welm
Alana L Welm

26 November 2020 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
ARAlessandra I. Riggio
Alessandra I. Riggio
KVKatherine E. Varley
Katherine E. Varley
AWAlana L. Welm
Alana L. Welm
Despite being the hallmark of cancer that is responsible for the highest number of deaths, very little is known about the biology of metastasis. Metastatic disease typically manifests after a protracted period of undetectable disease following surgery or systemic therapy, owing to relapse or recurrence. In the case of breast cancer, metastatic relapse can occur months to decades after initial diagnosis and treatment. In this review, we provide an overview of the known key factors that influence metastatic recurrence, with the goal of highlighting the critical unanswered questions that still need to be addressed to make a difference in the mortality of breast cancer patients.

8 September 2016 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
BHBethany Hannafon
Bethany Hannafon
YTYvonne D. Trigoso
Yvonne D. Trigoso
CCCameron L. Calloway
Cameron L. Calloway
YZY. Daniel Zhao
Y. Daniel Zhao
DLDavid H. Lum
David H. Lum
Wei-Qun DingWei-Qun Ding
Wei-Qun Ding
MicroRNAs are promising candidate breast cancer biomarkers due to their cancer-specific expression profiles. However, efforts to develop circulating breast cancer biomarkers are challenged by the heterogeneity of microRNAs in the blood. To overcome this challenge, we aimed to develop a molecular profile of microRNAs specifically secreted from breast cancer cells. Our first step towards this direction relates to capturing and analyzing the contents of exosomes, which are small secretory vesicles that selectively encapsulate microRNAs indicative of their cell of origin. To our knowledge, circulating exosome microRNAs have not been well-evaluated as biomarkers for breast cancer diagnosis or monitoring. Exosomes were collected from the conditioned media of human breast cancer cell lines, mouse plasma of patient-derived orthotopic xenograft models (PDX), and human plasma samples. Exosomes were verified by electron microscopy, nanoparticle tracking analysis, and western blot. Cellular and exosome microRNAs from breast cancer cell lines were profiled by next-generation small RNA sequencing. Plasma exosome microRNA expression was analyzed by qRT-PCR analysis. Small RNA sequencing and qRT-PCR analysis showed that several microRNAs are selectively encapsulated or highly enriched in breast cancer exosomes. Importantly, the selectively enriched exosome microRNA, human miR-1246, was detected at significantly higher levels in exosomes isolated from PDX mouse plasma, indicating that tumor exosome microRNAs are released into the circulation and can serve as plasma biomarkers for breast cancer. This observation was extended to human plasma samples where miR-1246 and miR-21 were detected at significantly higher levels in the plasma exosomes of 16 patients with breast cancer as compared to the plasma exosomes of healthy control subjects. Receiver operating characteristic curve analysis indicated that the combination of plasma exosome miR-1246 and miR-21 is a better indicator of breast cancer than their individual levels. Our results demonstrate that certain microRNA species, such as miR-21 and miR-1246, are selectively enriched in human breast cancer exosomes and significantly elevated in the plasma of patients with breast cancer. These findings indicate a potential new strategy to selectively analyze plasma breast cancer microRNAs indicative of the presence of breast cancer.

24 February 2022 in Nature Cancer
Verified
Journal Article
Open access
PDF file
KGKatrin P. Guillen
Katrin P. Guillen
MFMaihi Fujita
Maihi Fujita
ABAndrew J. Butterfield
Andrew J. Butterfield
SSSandra Daniela Scherer
Sandra Daniela Scherer
MBMatthew H. Bailey
Matthew H. Bailey
AWAlana L. Welm
Alana L. Welm
Models that recapitulate the complexity of human tumors are urgently needed to develop more effective cancer therapies. We report a bank of human patient-derived xenografts (PDXs) and matched organoid cultures from tumors that represent the greatest unmet need: endocrine-resistant, treatment-refractory and metastatic breast cancers. We leverage matched PDXs and PDX-derived organoids (PDxO) for drug screening that is feasible and cost-effective with in vivo validation. Moreover, we demonstrate the feasibility of using these models for precision oncology in real time with clinical care in a case of triple-negative breast cancer (TNBC) with early metastatic recurrence. Our results uncovered a Food and Drug Administration (FDA)-approved drug with high efficacy against the models. Treatment with this therapy resulted in a complete response for the individual and a progression-free survival (PFS) period more than three times longer than their previous therapies. This work provides valuable methods and resources for functional precision medicine and drug development for human breast cancer.

23 December 2021 in Cancer Cell
Verified
Journal Article
Open access
ALAnthony Letai
Anthony Letai
PBPatrick Bhola
Patrick Bhola
AWAlana L. Welm
Alana L. Welm
Functional precision medicine is a strategy in which live patient tumor cells are directly perturbed with drugs to provide immediately translatable, personalized information to guide patient therapy. The heterogeneity of human cancer has led to the realization that personalized approaches are needed to improve treatment outcomes. Precision oncology has traditionally used static features of the tumor to dictate which therapies should be used. Static features can include expression of key targets or genomic analysis of mutations to identify therapeutically-targetable “drivers.” While a surprisingly small proportion of patients receive clinical benefit from the static approach, functional precision medicine can provide additional information on tumor vulnerabilities. We discuss emerging technologies for functional precision medicine, as well as limitations and challenges to using these assays in the clinical trials that will be necessary to determine if functional precision medicine can improve patient outcomes and eventually become a standard tool in clinical oncology.

27 December 2016 in Cancer and Metastasis Reviews
Verified
Journal Article
Open access
PDF file
LDLacey E. Dobrolecki
Lacey E. Dobrolecki
SASusie D. Airhart
Susie D. Airhart
DADenis G. Alferez
Denis G. Alferez
SASamuel Aparicio
Samuel Aparicio
FBFariba Behbod
Fariba Behbod
Michael LewisMichael Lewis
Michael Lewis
Patient-derived xenograft (PDX) models of a growing spectrum of cancers are rapidly supplanting long-established traditional cell lines as preferred models for conducting basic and translational preclinical research. In breast cancer, to complement the now curated collection of approximately 45 long-established human breast cancer cell lines, a newly formed consortium of academic laboratories, currently from Europe, Australia, and North America, herein summarizes data on over 500 stably transplantable PDX models representing all three clinical subtypes of breast cancer (ER+, HER2+, and “Triple-negative” (TNBC)). Many of these models are well-characterized with respect to genomic, transcriptomic, and proteomic features, metastatic behavior, and treatment response to a variety of standard-of-care and experimental therapeutics. These stably transplantable PDX lines are generally available for dissemination to laboratories conducting translational research, and contact information for each collection is provided. This review summarizes current experiences related to PDX generation across participating groups, efforts to develop data standards for annotation and dissemination of patient clinical information that does not compromise patient privacy, efforts to develop complementary data standards for annotation of PDX characteristics and biology, and progress toward “credentialing” of PDX models as surrogates to represent individual patients for use in preclinical and co-clinical translational research. In addition, this review highlights important unresolved questions, as well as current limitations, that have hampered more efficient generation of PDX lines and more rapid adoption of PDX use in translational breast cancer research.